Paper Details

  1. Home
  2. Paper Details

Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease.

Author: DarkenPatrick, FernandezCarlos, FischerTracy, FogartyCharles, GoldenMichael, OrevilloChadwick, ReisnerColin, RennardStephen, RoseEarl St, TardieGregory

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.

Overview

Bronchodilators are medications that help to open up the airways in the lungs. They are commonly used to treat asthma and chronic obstructive pulmonary disease (COPD). Metered-dose inhalers (MDIs) are the most common way to deliver bronchodilators to patients. This article discusses the development of new MDIs that use a technology called porous-particle technology. This technology allows for the development of long-acting bronchodilators that can be delivered in a convenient and efficient way.
Paper Details　
Original Abstract of the Article :
Bronchodilator medications are central to the symptomatic management of chronic obstructive pulmonary disease (COPD). Metered-dose inhalers (MDIs) are the most commonly used devices to deliver treatment to patients with COPD and asthma, comprising approximately 70% of bronchodilator prescriptions. P...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124171/

データ提供：米国国立医学図書館（NLM）

Glycopyrronium: A New Hope for COPD Patients

Chronic obstructive pulmonary disease (COPD), a debilitating lung condition, affects millions worldwide. This study examines the safety, pharmacokinetics, and bronchodilatory efficacy of glycopyrronium, a long-acting muscarinic antagonist, delivered via a metered-dose inhaler (MDI) in patients with COPD. The researchers investigated the potential benefits of this novel approach to treating COPD.

A Breath of Fresh Air: Exploring New Horizons in COPD Treatment

The study found that glycopyrronium delivered via an MDI effectively improved lung function and provided bronchodilation in patients with COPD. This research highlights the potential of this new approach to managing COPD symptoms, offering a promising alternative for patients who may not respond well to traditional treatments. This is like navigating a desert: finding a new oasis, with a refreshing source of relief, can significantly improve the journey.

Navigating the Desert of COPD: Finding Relief from Symptoms

This research underscores the importance of exploring new and innovative approaches to managing COPD. It's like navigating a vast desert: finding a new oasis with a refreshing source of relief can significantly improve the journey. Always consult with a qualified healthcare professional for personalized advice and guidance on managing COPD.

Dr.Camel's Conclusion

This research offers a promising new approach to managing COPD, potentially providing a breath of fresh air for patients seeking relief from their symptoms. It's like finding a hidden oasis in the vast desert of COPD, offering a much-needed source of comfort and hope.

Date :
  1. Date Completed 2015-04-03
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

25027304

DOI: Digital Object Identifier

PMC4124171

Related Literature

Article Analysis
・Effects of glycopyrrolate oral inhalation
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.